ARTICLE
7 February 2022

DOJ's FCA Recoveries Hit A 7 Year High

KM
Katten Muchin Rosenman LLP

Contributor

Katten is a firm of first choice for clients seeking sophisticated, high-value legal services globally. Our nationally and internationally recognized practices include corporate, financial markets and funds, insolvency and restructuring, intellectual property, litigation, real estate, structured finance and securitization, transactional tax planning, private credit and private wealth.
In fiscal year 2021, DOJ's False Claims Act recoveries hit their highest level in seven years--$5.6 billion.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

In fiscal year 2021, DOJ's False Claims Act recoveries hit their highest level in seven years--$5.6 billion. Of that total, nearly $1.6 billion came from qui tam  lawsuits with relators taking home over $237 million. Yet again, the health care industry bore the brunt of these recoveries--nearly $5 billion. A new area of focus this year was Medicare Advantage plans (Medicare Part C), which many health care providers erroneously believe are not subject to the FCA or other federal anti-health care fraud laws. The flood of relators and FCA cases does not appear likely to stop under this administration--an average of 11 qui tam  actions were filed every week last fiscal year.

The Justice Department obtained more than $5.6 billion in settlements and judgments from civil cases involving fraud and false claims against the government in the fiscal year

https://www.justice.gov/opa/pr/justice-department-s-fal

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More